Jeff Walsh, Nvelop Therapeutics CEO

Two ex-blue­bird lead­ers launch Nvel­op with $100M to tack­le the biggest prob­lem in gene edit­ing

Nvel­op Ther­a­peu­tics launched Tues­day with $100 mil­lion in seed fund­ing to ad­vance re­search from the gene edit­ing pi­o­neers David Liu and Kei­th Joung, as they try to tack­le the field’s biggest prob­lem.

The Cam­bridge, MA start­up is the lat­est com­pa­ny to seek bet­ter ways to de­liv­er pow­er­ful gene-mod­i­fy­ing tools like CRISPR/Cas9, base edit­ing and prime edit­ing. While these edit­ing sys­tems hold vast po­ten­tial, they’ve been held back by a lack of op­tions to pack­age them and get them to the right places in the body.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.